A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.

医学 富维斯特朗 戈塞雷林 来曲唑 肿瘤科 内科学 三苯氧胺 实体瘤疗效评价标准 进行性疾病 乳腺癌 临床研究阶段 化疗 癌症 外科 妇科
作者
Lauren P. Cobb,Joseph Davis,Sara Hull,David Vining,Bryan Fellman,Ying Yuan,Shannon N. Westin,Jolyn Sharpe Taylor,Michael W. Bevers,Aaron Shafer,Nicole D. Fleming,Karen H. Lu,David M. Gershenson,Amir A. Jazaeri
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:40 (16_suppl): 5522-5522 被引量:15
标识
DOI:10.1200/jco.2022.40.16_suppl.5522
摘要

5522 Background: Neoadjuvant chemotherapy has demonstrated limited activity in low-grade serous carcinomas (LGSOC) of the ovary, fallopian tube, and peritoneum, with objective response rate of 11% and complete gross resection (CGR) rate of 38% at the time of interval cytoreductive surgery (ICS). LGSOC has many similarities to hormone receptor positive (HR+) breast cancer, including clinical benefit from endocrine therapies in the recurrent and maintenance settings. Based on the activity of antiestrogen plus CDK4/6 inhibitor combination therapy in HR+ breast cancer, we conducted a phase II pilot study to assess the clinical benefit of neoadjuvant treatment with fulvestrant and abemaciclib for women with advanced LGSOC. Methods: Women with unresectable, untreated stage III or IV LGSOC of the ovary, fallopian tube or peritoneum were eligible. Patients received fulvestrant (500 mg IM on day 1 and 15 of the first 28-day cycle, followed by day 1 of subsequent cycles) and abemaciclib 150 mg orally BID. Pre/perimenopausal patients also received goserelin 10.8 mg subcutaneously every 12 weeks for ovarian suppression. Patients continued treatment until deemed resectable by the treating surgeon with imaging re-assessment every 8 weeks using RECIST 1.1. Following ICS, patients receive 4 cycles of adjuvant fulvestrant and abemaciclib and then transition to maintenance letrozole. Patients with progressive disease (PD) were removed from study and received standard of care chemotherapy. Primary endpoint is clinical benefit rate (CBR). Results: Fifteen patients were enrolled and evaluable. At data cutoff date (January 20, 2022), 7 of 15 patients (47%) had partial response (PR) (one patient with radiologic PR had a pathologic complete response at ICS), 5 of 15 (33%) had stable disease (SD), and 3 of 15 (20%) had progressive disease (PD), resulting in a CBR of 80%. Of the 7 patients with PR, 3 have had ICS with CGR, 3 have not yet had ICS, and 1 underwent resection of supraclavicular disease with small volume residual disease in the chest. Of the 5 patients with SD, one underwent ICS with CGR, and two have been on treatment for 8 and 16 weeks with reduction in measurable disease but not yet deemed to be candidates for surgery. Four of the 5 patients (80%) who had ICS, had CGR. Median time on study prior to surgery was 24 weeks. Adverse events (grade 3 or 4) possibly related to abemaciclib occurred in 2 patients (13.3%) and included acute kidney injury (6.7%) and neutropenia (6.7%). Conclusions: Neoadjuvant treatment with fulvestrant and abemaciclib was tolerable and demonstrated unprecedented response and CGR rates in this pilot study. These results compare favorably to published outcomes of neoadjuvant chemotherapy in LGSOC. Further studies are planned to explore this new treatment option in a larger study population. Clinical trial information: NCT03531645.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小二郎应助coffee采纳,获得10
刚刚
Maor完成签到,获得积分0
刚刚
创新完成签到,获得积分10
刚刚
左丘冥发布了新的文献求助10
刚刚
忧郁绫发布了新的文献求助10
1秒前
李明发布了新的文献求助10
1秒前
叙余完成签到 ,获得积分10
1秒前
云澈完成签到,获得积分10
1秒前
2秒前
3秒前
3秒前
小二郎应助小粒橙采纳,获得10
3秒前
3秒前
研友_8yNA5L发布了新的文献求助10
3秒前
4秒前
雨落瑾年完成签到,获得积分10
4秒前
于浩发布了新的文献求助10
4秒前
小蘑菇应助束负允三金采纳,获得10
4秒前
DEF完成签到,获得积分10
4秒前
4秒前
5秒前
12完成签到,获得积分10
5秒前
bing完成签到,获得积分10
5秒前
小二郎应助饱满紫丝采纳,获得10
5秒前
5秒前
曦阳完成签到,获得积分10
5秒前
6秒前
张必雨发布了新的文献求助10
6秒前
6秒前
么么叽发布了新的文献求助10
6秒前
龙哥完成签到,获得积分10
6秒前
怡然问晴应助Jane采纳,获得10
6秒前
唐宁完成签到,获得积分10
6秒前
qiuqiu完成签到,获得积分10
7秒前
spoon1026完成签到,获得积分10
8秒前
不可靠月亮完成签到,获得积分10
8秒前
JamesPei应助豆芽采纳,获得10
8秒前
852应助熊一只采纳,获得10
9秒前
9秒前
很靠近海发布了新的文献求助30
9秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Les Mantodea de Guyane Insecta, Polyneoptera 1000
Conference Record, IAS Annual Meeting 1977 820
England and the Discovery of America, 1481-1620 600
Fault identification method of electrical automation distribution equipment in distribution networks based on neural network 560
Teaching language in context (Third edition) by Derewianka, Beverly; Jones, Pauline 550
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3581022
求助须知:如何正确求助?哪些是违规求助? 3150661
关于积分的说明 9483675
捐赠科研通 2852321
什么是DOI,文献DOI怎么找? 1568107
邀请新用户注册赠送积分活动 734388
科研通“疑难数据库(出版商)”最低求助积分说明 720670